Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kairos Pharma (KAPA) Change in Accured Expenses (2024 - 2025)

Kairos Pharma's Change in Accured Expenses history spans 2 years, with the latest figure at -$129000.0 for Q2 2025.

  • For Q2 2025, Change in Accured Expenses fell 637.5% year-over-year to -$129000.0; the TTM value through Jun 2025 reached -$246000.0, changed N/A, while the annual FY2025 figure was -$793000.0, 296.29% down from the prior year.
  • Change in Accured Expenses reached -$129000.0 in Q2 2025 per KAPA's latest filing, up from -$187000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $310000.0 in Q1 2024 to a low of -$191000.0 in Q3 2024.